

Research Transparency Panel Meeting Summary

Pfizer Inc.

14th December 2023 11:00am-12:00pm





Data Access Proposal Request

Flatiron Health UK RWD Products

Breast Cancer

Attendees

FLATIRON HEALTH UK

- Adam Manhi (chair)
- Liv Bryan (programme manager)

RESEARCH TRANSPARENCY PANEL

- Trishna Bharadia (patient)
- Hayley Hall (lay)
- Shira Peleg Hasson (clinical)
- Jennifer McCaffery (lay)
- Thomas Smith (patient)

Conflicts of interest

No conflicts declared by panel

Decision outcome

Approved

Summary of discussion

- Lay summary was clear and comprehensive, providing detailed context of the disease and treatment landscape (incl.statistics)
- Use cases were strong and well explained with clear objectives and specificity around how real-life patient benefit can be delivered
- A concise summary of analytics approaches and rationale by use case highlighted
- Clinical and commercial benefits clearly linked to addressing unmet needs in patients
- The panel raised several comments on other aspects of the application including:
 - Desire to see specific unmet needs within each use case description
 - Further explanation desirable around the potential benefits and impact of research on EDI and underrepresented populations
 - More direct linking of target outputs to patient benefit (e.g.patient/lay-focused channels)
 - Examples of third party companies (which provide data analytics support) desired

flatironhealth.co.uk © Flatiron Health | 2